By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Theraclone Sciences, Inc. 

Seattle Life Sciences Building
1124 Columbia Street, Suite 300
Seattle  Washington  98104  U.S.A.
Phone: 206-805-1600 Fax: 206-805-1699


SEARCH JOBS


Industry
Biotechnology

Segment
Life Sciences





Company News
Theraclone Sciences, Inc. Announces Exclusive Agreement With Gilead Sciences, Inc. (GILD) For Broadly Neutralizing HIV Antibodies 7/30/2014 9:34:50 AM
Theraclone Sciences, Inc. Announces Identification Of New Vulnerable Site On HIV Using Antibodies Discovered With Theraclone Technology 4/25/2014 7:50:28 AM
PharmAthene, Inc. (PIP) Terminates Merger Agreement With Theraclone Sciences, Inc. 12/2/2013 8:43:17 AM
Theraclone Sciences, Inc. Gets Bad News From Biomedical Advanced Research and Development Authority (BARDA) Regarding Pandemic Flu Drug 11/27/2013 7:44:03 AM
Theraclone Sciences, Inc. Presents Positive Data from Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection at ICAAC 2013 9/11/2013 9:46:14 AM
Theraclone Sciences, Inc. Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection 9/10/2013 9:36:06 AM
Theraclone Sciences, Inc. Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study 9/9/2013 10:33:38 AM
Few Redundancies' Between PharmAthene, Inc. (PIP) and Theraclone Sciences, Inc. Means No Layoffs 8/6/2013 8:10:48 AM
PharmAthene, Inc. (PIP) and Theraclone Sciences, Inc. Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets 8/1/2013 9:48:49 AM
Theraclone Sciences, Inc. Announces Positive Top-Line Data From Phase 1 Trial of Therapeutic Antibody for the Treatment of Human Cytomegalovirus Infection 4/2/2013 9:44:11 AM
123
//-->